Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-866949 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2010
At a glance
- Drugs BMS 866949 (Primary)
- Indications Depressive disorders
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 21 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 May 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 19 Feb 2010 Planned end date changed from 1 Mar 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.